In 2017, the companies of Kaluga Pharmaceutical Cluster increased their output of medicinal products by more than 80%. This was announced by the Governor of Kaluga region Anatoly Artamonov at the Russian Investment Forum in Sochi.
“In 2017, the output of medicinal products increased by more than 80%, while the manufacturing of locally made products rose by two to three times. We would like to bring the output to 7.5-8% of the total consumption in this market,” said the Governor, without specifying the current market share held by the region.
In 2016, the Kaluga cluster manufactured the finished dosage forms worth more than 12 billion rubles. According to Mr. Artamonov, currently, the drug pricing is one of the factors constraining the inflow of investments to the pharmaceutical industry. The Governor said that Kaluga region authorities are discussing the eventual compromise solutions with the Russian Ministry of Industry and Trade, the Ministry of Health, and the Federal Antimonopoly Service.
“On the one hand, we need to protect the interests of consumers so that these medicines are not very expensive. But, on the other hand, we need to consider the interests of manufacturers and find the right balance so that the manufacturing of drugs does not become unprofitable. Otherwise, we may put a stop on the inflow of investments to this industry,” said the head of the region.
Currently, the pharmaceutical companies of the cluster manufacture more than 50 medicinal products.